The Participant and Clinical Interactions Program (PCI) complements the work of the Integrating Special Populations Program, incentivizing clinical studies in special populations typically underrepresented in research, including pregnant women, infants and children, adolescents and young adults, elderly, rare orphan diseases, underserved/underrepresented minorities, rural populations, and populations with low socioeconomic status. PCI collaborates with the Community Engagement and Research Program and the Network Capacity Program to conduct Community Engagement Studios to understand community priorities for clinical research. In addition, PCI offers a Clinical and Translational Research Center WithOut Walls (CTRC-WOW) to facilitate community-based studies with mobile technologies, including wearables and virtual reality devices. In collaboration with the Regulatory Knowledge and Support Program, PCI will continue to implement and enhance processes for scientific review, registration and reporting, by providing tools and education for young investigators and investigators with limited experience conducting clinical trials. Building on the infrastructure previously established by the state-funded UCLA Health Alpha Clinic, PCI has created a Phase 1 unit providing highly specialized support to stem cell and gene therapy trials.

Services & Tools

Explore the Clinical and Translational Research Centers
Explore the size of potential research study cohorts from UCLA, local major health care providers, and CTSAs nationwide
Clinical trial support
CTSI ResearchGO provides a single portal to resources, expertise, and best practices for investigators, study staff, and partners/affiliates.

Highlighted services:

Program Aim

Ensure that research is safe, high-quality and responsive to community needs

  • Objective 1. Engage special populations in clinical research by creating a mobile clinical research center that aims to remove physical and geographic barriers thereby bridging the gap between community health care and clinical research
  • Objective 2. Use vouchers to incentivize research in special populations and broaden the research base
  • Objective 3. Create a Phase 1 clinical research unit focused on T1 and T2 clinical trials

Contact Us

For PCI questions, please contact the below personnel at each site.

PCI Leadership

Federman, Noah

Noah Federman, MD

Participant and Clinical Interactions Program Leader, Workforce Development Program Investigator
Arash Naeim

Arash Naeim, MD, PhD

Clinical & Translational Science Institute Co-Director, Senior Associate Director (Clinical Research), Network Capacity Program Leader, Participant and Clinical Interactions Program Leader, Regulatory Knowledge and Support Program Leader
Christina Wang

Christina Wang, MD

Clinical & Translational Science Institute Senior Associate Director, Lundquist/Harbor-UCLA Site Leader, Participant and Clinical Interactions Program Co-Leader, Workforce Development Program Co-Leader
Vargas, Roberto

Roberto Vargas, MD, MPH

Integrating Special Populations Program Co-Leader (Disparities), Participant and Clinical Interactions Program Co-Leader, Charles Drew University
Robert Jenders

Robert Jenders, MD, MS

Clinical & Translational Science Institute Senior Associate Director, Charles Drew University Site Leader, Biomedical Informatics Program Site Leader, Pilot Translational and Clinical Studies Program Co-Leader

PCI Investigators & Staff

Gutierrez, Raquel

Raquel Gutierrez

Site Administrator, Network Capacity Program Liaison Quality & Efficiency Council, Lundquist/Harbor-UCLA
Sanchez, Sarahmay

Sarahmay Sanchez

Network Capacity Program Research Coordinator Pool Director, Participant and Clinical Interactions Program Research Coordinator Credentialing
No image for this profile

Gregory Turner

Site Administrator, Network Capacity Program Administrator, Charles Drew University